The European Commission has sent a statement of objections to Servier SA alleging that the company willfully employed a series of negative practices to prevent or discourage other manufacturers from launching competitor products to its cardiovascular therapy Coversyl (perindopril).
The move against pay-for-delay practices comes as no surprise, but it caps a miserable few years for Servier and signals...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?